Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Leronlimab’s ability to downregulate intracellul

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 153886
(Total Views: 463)
Posted On: 02/03/2025 10:11:48 AM
Posted By: ohm20
Re: biloxiblues #149743
Quote:
Leronlimab’s ability to downregulate intracellular Ca²⁺ could indeed have interesting implications for transglutaminase-2 (TG2) activity, but calling it a cure for HIV would be a big leap. Here’s why:

HIV Persistence & Reservoirs – A true cure for HIV would require eliminating or functionally silencing latent viral reservoirs. Leronlimab primarily blocks the CCR5 co-receptor, preventing new infections but not necessarily eradicating existing reservoirs.



ChatGpt must not keep up with Dr. Sacha's work.

Quote:
3. Could This Prevent HIV Transmission?
A contraceptive for HIV (or a preventative method) would need to stop viral transmission at mucosal surfaces (vaginal, rectal, etc.).
Leronlimab primarily works inside immune cells, meaning it’s not directly a topical or systemic barrier against HIV entry like PrEP (e.g., Truvada, Descovy).



Leronlimab doesn't work inside immune cells, it blocks the cell surface expressed CCR5 receptor. ChatGpt doesn't think blocking HIV from entering the very cells it needs to reproduce is a barrier? Truvada and Descovy don't block entry of HIV, they stop the replication of the virus after it's already entered the cell.

Quote:
Leronlimab only works against CCR5-tropic HIV (~60-70% of new infections).



I don't know where they're getting 60% to 70% of new infections. Initial transmission of HIV via CXCR4 is fairly rare.


(13)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us